Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
235980.KQ
STRONG SELLREMOVEMedPacto, Inc. · Healthcare · South Korea · $80M · Avg Vol: $373K/d
MedPacto is a clinical-stage biotechnology company. It has no approved products or steady cash flows, making it a speculative binary bet that fails our Buffett margin of safety and Terry Smith quality compounder criteria.
COMPANY DESCRIPTION
MedPacto, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics for cancer and autoimmune diseases, with its lead candidate being vactosertib, a TGF-beta inhibitor. The company's competitive moat lies in its proprietary biomarker-driven drug discovery platform, which targets treatment-resistant cancers in combination with existing immunotherapies. MedPacto operates as a specialized oncology player with strategic global clinical partnerships.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | 3M | — |
| EPS | — | -0.60 | -1.10 | -0.39 | -0.25 | — |
| Shares | — | 25M | 34M | 34M | 34M | +38.8% |
| Debt | 33M | 42M | 2M | 1M | 1M | -57.1% |
| Equity | — | 21M | 47M | 38M | 30M | 12.5% |
| Op CF | — | -19M | -17M | -11M | -9M | — |
| Inv CF | — | 17M | 64M | -26M | 7M | — |
| Fin CF | — | 2M | 1M | -555,449 | -418,051 | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 235980.KQ are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| 235980.KQ | MedPacto, Inc.(you) | $80M | 6 | STRONG SELL |
| 456070.KQ | ENCell | $63M | 5 | STRONG SELL |
| 323990.KQ | Vaxcell-Bio Therapeutics Co., Ltd. | $88M | 2 | STRONG SELL |
| 166480.KQ | CORESTEMCHEMON Inc. | $69M | 9 | STRONG SELL |
| 095700.KQ | Genexine, Inc. | $111M | 7 | STRONG SELL |
| 011000.KS | GeneOne Life Science, Inc. | $68M | 1 | STRONG SELL |
| 389030.KQ | GENINUS Inc. | $74M | 14 | STRONG SELL |
| 321550.KQ | TiumBio Co., Ltd. | $127M | 7 | STRONG SELL |
| 203400.KQ | ABION Inc. | $54M | 2 | STRONG SELL |
| 338840.KQ | Y-Biologics | $136M | 3 | STRONG SELL |
Peer medians: ROE -1.1% · P/E 17.7x · Gross margin 43.6%